Close menu




December 16th, 2020 | 09:55 CET

E.ON, Sartorius, Defense Metals: The scarcer the goods, the higher the price

  • Investments
Photo credits: pixabay.com

Only in times of need do you realize what matters, and this is precisely what many businesses and private individuals are experiencing during the lockdown. Industry, too, can quickly find itself in need. The best example was the first few months of the pandemic when global supply chains broke down. Today, Asia is back on the growth path and the cargo ships are fully loaded. But the industry could still be in trouble - for example, if the energy supply collapses. Only recently, it became known that increasing electromobility is causing load peaks in the power grids - for example, after work. Utilities such as E.ON want to take countermeasures and, if need be, implement so-called "peak smoothing." This implementation plan would mean that charging stations would no longer be supplied with electricity when the grid load is high. Anyone still wanting to drive an electric vehicle in the evening would be left out in the cold.

time to read: 2 minutes | Author: Nico Popp
ISIN: CA2446331035 , DE000ENAG999 , DE0007165631

Table of contents:


    E.ON: Good conditions for rising share prices

    The above example shows how fundamentally essential consumers like E.ON are for Germany as an industrial location. The Company outsourced its conventional power generators a few years ago and is now focusing on regenerative energy as well as line networks. The latter in particular are becoming increasingly important - after all, regenerative power sources have to be connected to the grids. Many wind turbines in coastal regions only make sense if the electricity subsequently also flows to the industrial sites in southern Germany.

    Although E.ON's stock has lost 5.5% of its value over a one-year period, there is a growing conviction in the market that utilities also have prospects for investors. In particular, the promotion of sustainable investments could lead to suitable conditions for companies like E.ON. Added to this is the dividend yield of just under 5%. Given its low equity ratio, E.ON is not a classic value stock, but it is nevertheless well positioned.

    Sartorius: More than a pandemic profiteer

    Sartorius is also well positioned. The specialist for laboratory supplies and disposables in drug manufacturing is considered the Covid-19 stock apart from the vaccine manufacturers. Although the dividend is negligible after the share price gains, the payout could also go up again in the long term. After all, the business is running smoothly. For 2020, sales should climb by more than 20%. Sartorius should also continue to profit in 2021. After all, the production of drugs and vaccines is likely to continue at full speed in the coming year.

    Sartorius is also performing well away from the pandemic and acquired several areas at the end of 2019. Another positive is that Sartorius is well-positioned in Europe, the USA and Asia-Pacific. After nearly 100% in a year, the share could take a breather, but when this will happen remains uncertain. Sartorius' products and services are too much in demand, so market exaggerations are likely to continue.

    Defense Metals: Good underlying conditions, speculative share

    Defense Metals is still a long way from a share price performance like that of Sartorius. However, the Canadian Company is also sitting on an essential commodity: rare earths. 90% of this critical raw material is mined in China and found in many products, such as consumer electronics and rechargeable batteries. Defense Metals is developing one of the few rare earth properties in North America, emphasizing the strategic importance of the metals, including to the defence industry.

    Recently, Jamie Spratt, an expert in corporate finance, joined the Defense Metals team. The appointment is a sign that Defense Metals wants to get down to business as quickly as possible. The Company has an option to buy the Wicheeda rare earth project near the Canadian city of Prince George. Exploration drilling has already shown promise in recent months.

    Given the growing scarcity of rare earth metals and the simultaneous increase in demand for raw materials from regions with high environmental standards, the general conditions for Defense Metals are considered good. However, as the Company is still only valued at just over EUR 7 million, the stock must be regarded as speculative.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read